Hyperprogressive disease during PD-1 blockade in patients with advanced pancreatic cancer
The occurrence of markedly accelerated tumor growth during immunotherapy is considered a new mode of progression called hyperprogressive disease (HPD) and its impact on pancreatic cancer (PC) patients receiving immunotherapy is unknown. In this study, we described and explored the incidence, prognos...
Saved in:
Main Authors: | Shiyun Chen (Author), Lu Han (Author), Shiyuan Guo (Author), Zhaoli Tan (Author), Guanghai Dai (Author) |
---|---|
Format: | Book |
Published: |
Taylor & Francis Group,
2023-08-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Exploring prognostic factors for survival in patients with advanced pancreatic cancer undergoing PD-1 inhibitor immunotherapy
by: Yue Ma, et al.
Published: (2024) -
Hyperprogressive Disease in Cancers Treated With Immune Checkpoint Inhibitors
by: Pan Shen, et al.
Published: (2021) -
β-Glucan Combined With PD-1/PD-L1 Checkpoint Blockade for Immunotherapy in Patients With Advanced Cancer
by: Mengjie Wang, et al.
Published: (2022) -
Resistance to PD-1/PD-L1 blockade cancer immunotherapy: mechanisms, predictive factors, and future perspectives
by: Jin-Yu Sun, et al.
Published: (2020) -
Is hyperprogressive disease a specific phenomenom of immunotherapy?
by: Marta Brambilla, et al.
Published: (2020)